Brought to you by 
Servier gets rights to three of miRagen Therapeutics' microRNA-targeting cardiovascular compounds; deal terminated
20 Aug 2019
Executive Summary
Servier SA has licensed global rights (excluding the US and Japan) to several of miRagen Therapeutics Inc.’s (microRNA-based treatments) preclinical cardiovascular drug candidates. Included in the deal are MGN9103 and MGN1374 (inhibitors of miR208 and miR15/195, respectively) as well as an unidentified microRNA modulator.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Servier gets rights to three of miRagen Therapeutics' microRNA-targeting cardiovascular compounds; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice